Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer
Top Cited Papers
- 10 August 2015
- journal article
- review article
- Published by Springer Science and Business Media LLC in Oncogene
- Vol. 35 (15), 1877-1887
- https://doi.org/10.1038/onc.2015.287
Abstract
The last three decades have seen significant progress in our understanding of the role of the pro-survival protein BCL-2 and its family members in apoptosis and cancer. BCL-2 and other pro-survival family members including Mcl-1 and BCL-XL have been shown to have a key role in keeping pro-apoptotic 'effector' proteins BAK and BAX in check. They also neutralize a group of 'sensor' proteins (such as BIM), which are triggered by cytotoxic stimuli such as chemotherapy. BCL-2 proteins therefore have a central role as guardians against apoptosis, helping cancer cells to evade cell death. More recently, an increasing number of BH3 mimetics, which bind and neutralize BCL-2 and/or its pro-survival relatives, have been developed. The utility of targeting BCL-2 in hematological malignancies has become evident in early-phase studies, with remarkable clinical responses seen in heavily pretreated patients. As BCL-2 is overexpressed in ~75% of breast cancer, there has been growing interest in determining whether this new class of drug could show similar promise in breast cancer. This review summarizes our current understanding of the role of BCL-2 and its family members in mammary gland development and breast cancer, recent progress in the development of new BH3 mimetics as well as their potential for targeting estrogen receptor-positive breast cancer.Keywords
This publication has 114 references indexed in Scilit:
- Structure-guided design of a selective BCL-XL inhibitorNature Chemical Biology, 2013
- Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-BCell Death & Disease, 2012
- The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroupsNature, 2012
- Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer CellsCancer Cell, 2012
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast CancerThe New England Journal of Medicine, 2012
- A Five-Gene Model Predicts Clinical Outcome in ER+/PR+, Early-Stage Breast Cancers Treated with Adjuvant TamoxifenHormones and Cancer, 2011
- A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER‐positive breast cancerThe Journal of Pathology, 2011
- BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy receivedBritish Journal of Cancer, 2010
- BIM Regulates Apoptosis during Mammary Ductal Morphogenesis, and Its Absence Reveals Alternative Cell Death MechanismsDevelopmental Cell, 2007
- The Bcl-2 apoptotic switch in cancer development and therapyOncogene, 2007